Want to join the conversation?
Pharmaceutical company $ALXN delivered total YoverY revenue growth of 18% and volume growth of 23% in 2Q16, driven by the strength of its three marketed therapies. Soliris grew with a steady number of new patients with PNH and aHUS being treated globally. Strensiq is a new driver of growth and Kanuma continued to progress.
Any idea why some investors are happy about the disastrous $UA results??
Wow! GM killed it with earnings today! Did not expect this after $F gave the feeling it will eclipse the Chevy maker completely!
Oil rebound starting to show up in energy stocks. $XOM $CVX
I have a feeling "CLOUDy" days are ahead, with $AMZN leading the pack.
$AAL is giving pay hikes to its employees but investors are sulking.